investors
LegoChem Biosciences Wins 'Best ADC Platform Technology' at World ADC Awards 2023
2023.10.19
LegoChem Biosciences
Wins 'Best ADC Platform Technology' at World ADC Awards 2023
- Clinches Prestigious Award for the 5 Consecutive Years, Recognized for Unparalleled Technological Expertise by Industry Leaders
- Provides Insights into Pre-clinical and Clinical Progress on Trop2-ADC, Claudin18.2-ADC, and More
LegoChem BioSciences Co., Ltd. (141080KS, referred to as 'LEGOChem Bio') has been honored with the esteemed 'Best ADC Platform Technology' award at the 'World ADC Awards 2023,' held on October 18th in San Diego, USA. This category featured a competitive field of 7 contenders, including Synaffix, WuxiXDC, and Ajinomoto. This remarkable achievement marks LegoChem Bio's 5th consecutive win, except for the previous year when it did not participate, solidifying its reputation as a foremost industry leader, as acclaimed by experts in the field.
Mr. Jae-wook Chae, Vice President and head of global business development at the Boston branch, remarked, 'In light of the increasing concerns surrounding ADC-related side effects, our ADC linker technology is gaining substantial recognition as a pioneering solution to toxicity issues.' He further stated, 'Leveraging this technological prowess, we are currently engaged in discussions with global pharmaceutical companies for diverse collaborative opportunities.'
CEO Mr. Yong-joo Kim recently announced the 'VISION 2030' strategy, outlining the company's ambitious plans to actively secure 15 to 20 development pipelines within the next 5 years, positioning LegoChem Bio as the Premier company in the industry.
During the conference, LegoChem Bio also delivered verbal presentations on LCB84 (Trop2-ADC), on the edge of commencing its first patient dosing in the United States, highlighting its minimal toxicity and exceptional cancer targeting compared to competing drugs. Additionally, the company unveiled non-clinical data for Claudin18.2-ADC, known as LCB02A, marking its Debut release. This data showcased promising efficacy results in patient-derived gastric and pancreatic cancer cell-based animal models. LegoChem Bio aims to submit an Investigational New Drug (IND) application to the U.S. FDA in the first half of 2025.
- Clinches Prestigious Award for the 5 Consecutive Years, Recognized for Unparalleled Technological Expertise by Industry Leaders
- Provides Insights into Pre-clinical and Clinical Progress on Trop2-ADC, Claudin18.2-ADC, and More
LegoChem BioSciences Co., Ltd. (141080KS, referred to as 'LEGOChem Bio') has been honored with the esteemed 'Best ADC Platform Technology' award at the 'World ADC Awards 2023,' held on October 18th in San Diego, USA. This category featured a competitive field of 7 contenders, including Synaffix, WuxiXDC, and Ajinomoto. This remarkable achievement marks LegoChem Bio's 5th consecutive win, except for the previous year when it did not participate, solidifying its reputation as a foremost industry leader, as acclaimed by experts in the field.
Mr. Jae-wook Chae, Vice President and head of global business development at the Boston branch, remarked, 'In light of the increasing concerns surrounding ADC-related side effects, our ADC linker technology is gaining substantial recognition as a pioneering solution to toxicity issues.' He further stated, 'Leveraging this technological prowess, we are currently engaged in discussions with global pharmaceutical companies for diverse collaborative opportunities.'
CEO Mr. Yong-joo Kim recently announced the 'VISION 2030' strategy, outlining the company's ambitious plans to actively secure 15 to 20 development pipelines within the next 5 years, positioning LegoChem Bio as the Premier company in the industry.
During the conference, LegoChem Bio also delivered verbal presentations on LCB84 (Trop2-ADC), on the edge of commencing its first patient dosing in the United States, highlighting its minimal toxicity and exceptional cancer targeting compared to competing drugs. Additionally, the company unveiled non-clinical data for Claudin18.2-ADC, known as LCB02A, marking its Debut release. This data showcased promising efficacy results in patient-derived gastric and pancreatic cancer cell-based animal models. LegoChem Bio aims to submit an Investigational New Drug (IND) application to the U.S. FDA in the first half of 2025.